Last edition
News about "all-oral AML treatment"
US FDA Approves INQOVI Plus Venetoclax for AML
The US Food and Drug Administration (FDA) approves INQOVI with venetoclax as the first all-oral combination treatment for acute myeloid leukemia patients ineligible for intensive chemotherapy, supported by positive ASCERTAIN-V trial data.
All-oral AML Treatment | 14/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members